Evidence map›Paper›PMID 29961124›Full record

ReviewPsychopharmacology2018

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression.

Marion J F Levy, Fabien Boulle, Harry W Steinbusch, Daniël L A van den Hove, Gunter Kenis, Laurence Lanfumey

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 4 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 4 syntheses or guidelines pooled it, 299 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Marion J F LevyCentre de Psychiatrie et Neurosciences (Inserm U894), Université Paris Descartes, 102-108 rue de la santé, 75014, Paris, France.
Fabien BoulleCentre de Psychiatrie et Neurosciences (Inserm U894), Université Paris Descartes, 102-108 rue de la santé, 75014, Paris, France.
Harry W SteinbuschDepartment of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.
Daniël L A van den HoveDepartment of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.
Gunter KenisDepartment of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.
Laurence LanfumeyCentre de Psychiatrie et Neurosciences (Inserm U894), Université Paris Descartes, 102-108 rue de la santé, 75014, Paris, France. laurence.lanfumey@inserm.fr.
European Graduate School of Neuroscience · NLInserm · FRUniversité Paris Cité · FR

Funding

Agence Nationale de la Recherche 2011-BSV-017-01Internationale Stichting Alzheimer Onderzoek 12530
6 · The paper itself

Abstract

Depression is a major health problem with a high prevalence and a heavy socioeconomic burden in western societies. It is associated with atrophy and impaired functioning of cortico-limbic regions involved in mood and emotion regulation. It has been suggested that alterations in neurotrophins underlie impaired neuroplasticity, which may be causally related to the development and course of depression. Accordingly, mounting evidence suggests that antidepressant treatment may exert its beneficial effects by enhancing trophic signaling on neuronal and synaptic plasticity. However, current antidepressants still show a delayed onset of action, as well as lack of efficacy. Hence, a deeper understanding of the molecular and cellular mechanisms involved in the pathophysiology of depression, as well as in the action of antidepressants, might provide further insight to drive the development of novel fast-acting and more effective therapies. Here, we summarize the current literature on the involvement of neurotrophic factors in the pathophysiology and treatment of depression. Further, we advocate that future development of antidepressants should be based on the neurotrophin theory.

Indexed as

AffectAnimalsAntidepressive AgentsBiomarkersBrain-Derived Neurotrophic FactorDepressionEmotionsHumansNerve Growth FactorsNeuronal PlasticitySignal TransductionTreatment OutcomeAntidepressive AgentsBiomarkersBrain-Derived Neurotrophic FactorNerve Growth FactorsAntidepressantGrowth factorsMoodNeurocircuitsPlasticity

Identifiers

PMID29961124
PMCPMC6061771
OpenAlexW2810237733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.